BioNTech's stock fell 7.13% after its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab failed to meet the primary endpoint for progression-free survival. This setback has shaken investor confidence in BioNTech's mRNA oncology pipeline and triggered an investigation into whether the company misled shareholders about the clinical progress of its cancer immunotherapy programs. Investors who suffered losses are encouraged to submit their information for a potential securities claim. The investigation focuses on possible false or misleading statements made by BioNTech regarding the trial outcomes and program prospects.
BioNTech's stock is trading slightly up by 0.24% on Pluang, priced at USD 89.22 as of Oct 15, 2026 02:31 WIB. Despite recent setbacks and an ongoing investigation, the stock remains closer to its 52-week low of USD 83.89 than its high of USD 119.34, with a market cap of $22.36 billion.
BioNTech's experimental cancer treatment BNT113, combined with pembrolizumab, failed to show a significant improvement in progression-free survival in its Phase 2/3 AHEAD-MERIT trial. Despite missing this first primary endpoint, the trial will procee...
BioNTech announced that its Phase 2/3 trial of mRNA cancer immunotherapy BNT113 combined with pembrolizumab did not meet the first primary endpoint of progression-free survival in treating HPV16-positive head and neck cancer. However, the trial will ...
